Get started
Work

Abstract PS1-08-26: A phase 1/2, multi-part, open-label study of FWD1802, a novel oral selective estrogen receptor degrader (SERD), in patients with ER+/ HER2- locally advanced or metastatic breast cancer (BC)

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps1-08-26
Authors: Y. Meng, F. Xu, X. Qu, Y. Shi, H. Li, Y. Sun, X. Wang, H. Liu, S. Ding, H. Hu, H. Li, J. Li, M. Yan, Y. Yin, T. Sun, W. Xie, X. Chen, J. Wang, C. Zhu, J. Zhang
Institutions: Fudan University, Fudan University Shanghai Cancer Center, Sun Yat-sen University, Sun Yat-sen University Cancer Center, First Hospital of China Medical University, China Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Shandong Tumor Hospital, Sichuan Cancer Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Jilin Province Tumor Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, Jiangsu Province Hospital, Liaoning Cancer Hospital & Institute, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Second People’s Hospital of Yibin
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129493068
Cites:
Cited by:
Related to: